Role of cardiac factors in the initial hypotensive action by beta-adrenoreceptor blocking agents

Insights

The initial drop in blood pressure from beta-blockers like timolol maleate involves reduced cardiac output and increased oxygen use, suggesting tissue underperfusion contributes to their hypotensive effect.

Area of Science:

  • Cardiovascular Pharmacology
  • Hypertension Research
  • Hemodynamics

Background:

  • The delayed blood pressure decrease following beta-blockade is not well understood.
  • Limited data exists on hemodynamic changes during the initial hypotensive action of beta-blockers.

Purpose of the Study:

  • To investigate the early hemodynamic events associated with the hypotensive action of timolol maleate.
  • To explore the relationship between initial hemodynamic changes and subsequent blood pressure reduction.

Main Methods:

  • Hemodynamic measurements (mean arterial blood pressure, cardiac output, arteriovenous oxygen difference) were taken in 10 essential hypertension patients.
  • Frequent measurements were conducted for the first 30 hours after the initial dose, with follow-ups at 3 and 6 weeks.

Main Results:

  • A significant blood pressure decrease (13.5 +/- 8.2 mm Hg) was observed by 3 hours after the first dose.
  • This was preceded by an initial decrease in cardiac output and an increase in arteriovenous oxygen difference, without immediate blood pressure fall.
  • The magnitude of initial cardiac output decrease and arteriovenous oxygen difference increase correlated with later blood pressure reduction.

Conclusions:

  • Early tissue underperfusion, indicated by decreased cardiac output and increased arteriovenous oxygen difference, may play a role in the initial hypotensive effect of beta-blockers.
  • Hemodynamic patterns differ between early and late treatment phases, similar to other antihypertensive agents.

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...